Focused ultrasound could be a game-changer for urological conditions.

The technology has a significant track record in the treatment of prostate cancer, with more than 40,000 patients treated worldwide and 15 years of follow-up study data. To date, Europe and some regions of Asia have approved the use of focused ultrasound to treat prostate cancer and kidney cancer. In the US, two systems have been approved by the Food and Drug Administration (FDA) to treat abnormal prostate tissue, (including prostate cancer and benign prostate hypertrophy (BPH). Additional methods to treat the prostate, including MR-guidance and a trans-urethral approach, are being researched worldwide.

There is also clinical and preclinical research happening around the globe to assess the potential of the technology to treat kidney and bladder cancer, acute tubular necrosis, acute kidney injury, kidney stones and ureterocele.

Learn more about focused ultrasound for:

clinical stages key
Acute Kidney Injury Early Stage icon    
Acute Tubular Necrosis Early Stage icon    
Benign Prostatic Hyperplasia (BPH) FDA Approved icon Outside Approval icon Clinical Trials icon
Bladder Tumors Early Stage icon    
Kidney Tumors Outside Approval icon Clinical Trials icon  
Kidney Stone Fragmentation Early Stage icon    
Kidney Stone Propulsion Clinical Trials icon    
Prostate Cancer FDA Approved icon Outside Approval icon Clinical Trials icon
Ureterocele Early Stage icon